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Background: Men of African descent have the highest incidence and mortality rates of prostate cancer (PrCa)
worldwide. Notably, PrCa is increasing in Africa with Nigerian men being mostly affected. Thus, it is important to
understand risk factors for PrCa in Nigeria and build capacity for cancer research. The goals of this study were to
determine the feasibility of conducting an epidemiological study of PrCa and to obtain preliminary data on risk
factors for PrCa in Nigeria.
Methods: A case–control study (50 cases/50 controls) was conducted at the University College Hospital (UCH) in
Ibadan, Nigeria, between October 2011 and December 2012. Men aged 40 to 80 years were approached for the study
and asked to provide informed consent and complete the research protocol. Logistic regression models were used to
examine associations between demographic, social and lifestyle characteristics and risk of PrCa.
Results: The participation rate among cases and controls was 98% and 93%, respectively. All participants completed a
questionnaire and 99% (50 cases/49 controls) provided blood samples. Cases had a median serum diagnostic PSA of
73 ng/ml, and 38% had a Gleason score 8–10 tumor. Family history of PrCa was associated with a 4.9-fold increased risk
of PrCa (95% CI 1.0 - 24.8). There were statistically significant inverse associations between PrCa and height, weight and
waist circumference, but there was no association with body mass index (kg/m2). There were no associations between
other socio-demographic and lifestyle characteristics and PrCa risk.
Conclusion: This feasibility study demonstrated the ability to ascertain and recruit participants at UCH and collect
epidemiological, clinical and biospecimen data. Our results highlighted the advanced clinical characteristics of PrCa in
Nigerian men, and that family history of PrCa and some anthropometric factors were associated with PrCa risk in this
population. However, larger studies are needed to better understand the epidemiological risk factors of PrCa in Nigeria.
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Prostate cancer (PrCa) is the most commonly diagnosed
solid tumor in men and the second leading cause of
cancer-related deaths in developed countries [1-3]. This
cancer has a complex, multi-factorial etiology and both
genetic and environmental/lifestyle factors contribute to
its development [4]. Although extensive research has been* Correspondence: ilir.agalliu@einstein.yu.edu
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established epidemiological risk factors are age, race/eth-
nicity and family history of PrCa [2,5,6]. There is a large
variation in PrCa rates internationally with men of African
and Afro-Caribbean descent having the highest incidence
of and mortality from this cancer [7-9]. Family history of
PrCa among first-degree relatives is associated with a sig-
nificant, 2- to 3-fold increased risk of PrCa [10,11], and
both early ages at diagnosis and multiple affected family
members are strong predictors of risk in relatives.
The role of other putative factors in PrCa etiology includ-
ing smoking, alcohol, obesity, diet, and androgens is incon-
clusive with some studies reporting positive associations,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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indicate that higher intake of foods rich in antioxidants
such as vitamins C and E, lycopene, β-carotene, selenium
and cruciferous vegetables are inversely associated with
PrCa risk, whereas consumption of foods that may in-
crease oxidative stress, including saturated fats and red
meat is associated with increased risk [13,16,21-28]. Lastly,
body mass index (BMI)/obesity have been positively asso-
ciated with PrCa, especially with risk of advanced grade/
stage cancer [20,29,30]. Although the large international
variation in PrCa incidence and mortality rates could
partly be due to differences in age distribution, access to
health care, and screening services, cultural and other fac-
tors including genetic susceptibility, and rapid changes in
diet and lifestyle factors, particularly in developing coun-
tries, may also contribute to this disparity [31-33].
Data from the GLOBOCAN program of the Inter-
national Agency for Research on Cancer (IARC) show that
PrCa is also the leading cancer in sub-Saharan African
men, accounting for 14% of all cancer diagnoses and 12%
of all cancer-related deaths [34,35]. Men in Nigeria suffer
the highest burden from PrCa with estimated annual age-
adjusted incidence and mortality rates of 22.7 and 18.6 per
100,000, respectively. This accounts for 18.2% and 17.7%
of all cancer-related diagnoses and deaths, respectively, in
men in this region [7,34,35]. Given that Nigeria is the
most populous country in Africa with an estimated popu-
lation of 160 million in 2012, the rates and percentages
above translate to an enormous burden in absolute num-
bers of men affected by PrCa.
The few published case-series reports on PrCa in
Nigeria demonstrate an increasing trend in incidence over
a 30-year period raising it from the 8th to the 1st ranked
cancer [36-38]. Furthermore, data from previous reports
[37,39-43] show that 65% to 80% of all PrCa patients in
Nigeria are diagnosed with advanced tumor stage and
grade, and men affected by PrCa in this country have the
lowest 5-year survival rates in the world. While the above
data demonstrate the need to urgently investigate PrCa in
Nigeria, the reported numbers are likely to be an under-
estimate of the true burden of PrCa, since most of the re-
ports are based on limited population and incomplete
cancer registry data [9].
Therefore, it is important to conduct large studies to
better understand epidemiological risk factors for PrCa
morbidity and mortality in Nigerian men as well as to
build capacity for cancer research and biospecimen col-
lection and storage in Nigeria. As an initial step toward
this goal, a collaboration was initiated between Albert
Einstein College of Medicine in New York City and the
University College Hospital (UCH) in Ibadan, in order to
assess the feasibility of conducting a small, hospital-based
case–control study of PrCa at the latter institution. The
primary goals of the study were to assess participationrates of PrCa patients and controls at UCH, to investigate
the feasibility of collecting, storing and analyzing bio-
specimens in partnership with UCH, and to obtain pre-
liminary estimates on the prevalence of various potential
risk factors for PrCa in Nigerian men. An additional ob-
jective was to start building capacity and infrastructure to
conduct high quality epidemiological and clinical research
studies on cancer in Nigeria.
Methods
Study population and data collection
A hospital-based case–control study of PrCa (50 cases/50
controls) was conducted at University College Hospital
(UCH), a major tertiary hospital and academic medical
center established in 1957 in Ibadan, Nigeria. The recruit-
ment of participants started in October 2011 and ended in
December 2012; however, the active recruitment period
was 13 months because of several interruptions during
this period due to strikes that affected hospital operations.
Ethical approval for the study was sought and obtained
from the Institutional Review Boards (IRBs) of the Albert
Einstein College of Medicine in New York City and the
University College Hospital in Ibadan, Nigeria, before re-
cruitment started.
Ascertainment of participants
Cases were incident prostate cancer patients, aged 40 to
80 years at diagnosis, who were admitted and/or undergo-
ing treatment for PrCa at UCH during the ascertainment
period. They were identified by reviewing medical records
and patients’ appointments, primarily from Urology. All
patients with a histologically-confirmed prostate tumor of
any grade were eligible for the study; a case was consid-
ered incident if the initial diagnosis of PrCa was within
6 month-period before contact with the patient. Cases
underwent a chart review to confirm their PrCa diagnosis
and tumor characteristics. Men younger than 40 years of
age were excluded because invasive PrCa is very rare in
this group. We also excluded men aged over 80 years be-
cause of potential comorbidity issues and the challenge in
conducting interviews in this age group.
The designated resident doctor at Urology and the study
coordinator reviewed medical records on a weekly basis to
identify potentially eligible patients and their appointment
dates. Patients were approached during their Urology clinic
visit or within 72 hours of admission to the hospital by the
study coordinator or the senior registrar in Clinical Epi-
demiology in order to explain the purpose of the study, and
obtain informed consent. The informed consent assessed
willingness to participate at different levels: Level 0- refusal
to participate in any aspect of the study (administer short
debriefing survey to inquire about reason(s) for non-
participation); Level 1- willingness to complete a structured
interview that collected information about PrCa risk factors
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cords; Level 2- Level 1 and provide a blood specimen; or
Level 3- Level 1 and provide a buccal cells sample (for pa-
tients that refused to provide a blood sample). The in-
formed consent and study instruments were provided in
either English or Yoruba (the most prevalent indigenous
language in Ibadan) to accommodate participants who did
not speak English fluently, although English is the official
language spoken in Nigeria.
A total of 52 potentially eligible cases were identified
during the ascertainment period, but 51 were approached
for the study (one patient died before he was contacted).
Of the 51 eligible patients, 50 (98%) agreed to participate
in the study. All 50 enrolled prostate cancer patients pro-
vided written informed consent and elected Level 2 par-
ticipation (i.e., completed a structured interview, gave
permission to have their medical records reviewed, and
provided a blood sample for genomic DNA).
Controls were men aged 40 to 80 years, who did not
have a prior history of or symptoms related to PrCa, and
they were frequency-matched to cases by 5-year age
group. The controls were recruited from hospital depart-
ments and services that were not linked to Urology,
namely Orthopedics, Ophthalmology, Internal Medicine
and the Hypertensive Clinic, during the same ascertain-
ment period as that for the cases. The study coordinator
and medical residents reviewed medical records on a
weekly basis to identify potential control participants. Eli-
gible controls were approached at clinic visits or within
72 hours of admission to the hospital by the study coord-
inator and designated senior registrar in Clinical Epidemi-
ology to explain the purpose of the study, and obtain
informed consent. The informed consent process used
was similar to that described for cases in order to assess
different levels of participation; the only difference was
that controls were asked to provide an additional blood
sample (8 ml vial in a red top tube) for separation of
serum that was used to measure their serum PSA levels.
A total of 54 eligible controls were approached for the
study during the recruitment period. Of these, 50 (93%)
agreed to participate, provided written informed consent,
and completed the structured interview. Of the 50 en-
rolled controls, 99% (49/50) provided blood samples for
serum and genomic DNA (one patient refused to provide
blood and mouthwash).
Questionnaire data and specimen collection
All enrolled participants (50 cases/50 controls) completed
a structured questionnaire with a male interviewer at the
time of recruitment, after signing the informed consent
form. The questionnaire collected information on demo-
graphic, anthropometric, lifestyle and social characteris-
tics, information about family size and structure, family
history of PrCa, as well as other cancers in first- andsecond-degree relatives, and medical history, including
frequency of major comorbid conditions and physician
visits over the past five years. We also assessed dietary pat-
terns and habits in the year before interview. Information
about PrCa was collected for the cases by inquiring about
signs and symptoms preceding cancer diagnosis, the time
interval between any symptoms and the diagnosis date,
and how the cancer was first detected.
After the interview, both cases and controls provided a
blood sample that was collected in one 6 ml green top
tube (heparin) and that was used to extract genomic DNA
for future studies. In controls, we collected an additional
vial of blood in an 8 ml red top tube to separate serum,
which was used to measure their serum PSA at the time
of recruitment. We did not measure serum PSA levels in
cases since blood samples were collected after PrCa diag-
nosis and treatment. However, for PrCa cases information
on diagnostic serum PSA levels was extracted from med-
ical records. All blood samples were collected by a trained
phlebotomist and transported to the laboratory at UCH in
cold containers within two hours of obtaining samples.
DNA was extracted from white blood cells (the buffy coat
layer) following the laboratory instructions included with
the Nucleon BACC2 Kit from GE Health Care Europe.
Total serum PSA was measured using VIDAS® tPSA assay
in controls. All blood, serum and DNA samples were
stored in a −20°C freezer in laboratories at UCH.
Statistical analyses
We compared the demographic, social, lifestyle and dietary
factors between cases and controls using Student t-tests
(for continuous normally-distributed variables), Wilcoxon
rank-sum test (for continuous non-normally-distributed
variables) and chi-square tests (for categorical variables).
All tests were two-sided using a significance level α = 0.05.
Unconditional logistic regression models were used to esti-
mate odds ratios (ORs) and 95% confidence intervals (CI)
for the associations between various exposures of interest
and PrCa risk, with adjustment for age [44]. Since the sam-
ple size for this feasibility study was small we did not have
sufficient statistical power to conduct multivariate model-
ing or stratified analyses.
Results
Table 1 provides a description of demographic and social
characteristics of the 50 PrCa patients and 50 controls re-
cruited into the study. Participants were, on average,
69 years old and the majority was of Yoruba ethnicity (88%
of cases and 96% of controls). A first-degree family history
of PrCa was associated with a 4.9-fold increased risk of
PrCa (95%CI 1.0 - 24.8). There was only one control who
reported a second-degree relative with PrCa, but none of
the cases did. With regard to social factors, controls were
more likely to be professionals with slightly higher college
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characteristics was statistically significantly different be-
tween the two groups. The average annual income in this
population was low (equivalent to US $20-$50) since the
majority of participants were retired. However, it was simi-
lar between cases and controls.Table 1 Selected demographic and social characteristics of pr
Characteristics Cases (n = 50)
n %
Age at interview (years)
45 - 59 5 10.0
60 - 69 20 40.0
















None or <4 yrs 7 14.0
4-18 yrs 27 54.0
College degree/Graduate 16 32.0
Employment status




Managerial, technical or administrative 14 28.0







*OR and 95% CI were estimated from logistic regression models adjusted for age; O
†Other ethnicities include Benin, Ebira, Edo, Hausa, Ibo, Ibibio, Ofemai.
‡First-degree relative includes father, brother(s) or son(s).
ξOR and 95% CI are expressed per one unit increase (number of biological childrenWe compared several anthropometric, lifestyle and diet-
ary characteristics between PrCa patients and controls
(Table 2). There were statistically significant inverse associa-
tions between risk of PrCa and height (OR = 0.91, 95% CI
0.86-0.97; per one cm increase), weight (OR = 0.97, 95% CI
0.94-1.00; per one kg increase; borderline significant), andostate cancer cases and controls







48 96.0 1.00 -
2 4.0 3.42 0.63 18.62
0.046
48 96.0 1.00 -




6.26 3.03 0.16 1.10ξ 0.96 1.26
0.53
33 66.0 1.00 -
17 34.0 1.26 0.55 2.91
-
0.26
8 16.0 1.00 -
19 38.0 1.63 0.50 5.31
23 46.0 0.80 0.24 2.69
0.14
20 40.0 1.00
30 60.0 2.03 0.82 5.03
0.43
15 30.0 1.00 -
15 30.0 1.27 0.44 3.70
8 16.0 2.73 0.86 8.65
6 12.0 1.13 0.27 4.73
6 12.0 0.91 0.21 4.01
0.67
15 30.0 1.00 -
19 38.0 0.75 0.29 1.90
16 32.0 0.64 0.24 1.75
R = 1.00 refers to the reference category.
).
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crease). However, there was no difference in body mass
index (BMI) between the two groups. The proportion of
men who had lost 5 kg or more in the past year was
higher in cases in comparison to controls (52% vs. 16%;
p < 0.0001), which could potentially be attributed to
cachexia due to cancer.
There was no association between smoking and PrCa
(Table 2). The majority of participants (58% of cases and
66% of controls) were never cigarette smokers and 50%
of former smokers had quit cigarettes more than
27 years ago. In relation to alcohol use, former drinkers
had an OR = 5.2 (95% CI 1.86 - 15.56) for PrCa in com-
parison to never drinkers. Moreover, cases stopped
drinking alcohol on average 10 years more recently then
controls (p = 0.008). Nonetheless, there was no clear
pattern between alcohol use and PrCa since the propor-
tion of current drinkers and the average number of
drinks/week was higher in controls in comparison to
cases. We also queried cases and controls about their
dietary habits in the year before interview date, and
assessed different food items that are consumed in
Nigeria (Table 2). The intake of several foods such as
vegetables, saturated fats, unsaturated fats (olive and
canola oil) and milk or yogurt differed between cases
and controls. However, the only statistically significance
difference was for unsaturated fats, where men in the
highest vs. lowest category had an OR of 0.15 (95% CI
0.05-0.48) for PrCa. There were no clear trends across
increasing categories for other food items, which could
also be due to small sample size.
The average (SD) age at PrCa diagnosis for the cases
was 69 (7.4) years, and the average (SD) elapsed time
between PrCa diagnosis and interview date was 0.54
(0.67) months. The majority (76%) of the cases were di-
agnosed because of symptoms (e.g., urinary frequency,
pain, blood in urine) that led them to hospitalization,
while 12% of them were diagnosed because of an abnor-
mal digital rectal exam (DRE) or high serum PSA levels
(Table 3). We queried both cases and controls regarding
PSA and DRE screening for PrCa; 98% of PrCa patients
reported having had a serum PSA or digital rectal exam
(DRE) before their cancer diagnosis, and the median
diagnostic PSA was 72.9 ng/ml and 70% of patients has
a PSA > 20 ng/ml. In addition, 32% and 38% of prostate
tumors were of Gleason scores of 7 or 8–10, respect-
ively (Table 3). Information on clinical stage of PrCa
was not available, because cancer staging is currently
not performed in routine clinical practice in Nigeria.
However, approximately 90% of the PrCa patients in this
study received radiation, hormone therapy or orchiec-
tomy, which are indications for treatment of regional or
metastatic tumor stage. In relation to PrCa screening,
80% of controls had never had a serum PSA or DRE(Table 3). In our study, we also measured serum PSA
levels in controls from the blood that they provided at
the time of interview. Their median serum PSA was
2.13 ng/ml. However, 18% of controls had serum PSA
values between 4.0 and 9.9 ng/ml, and 8% had PSA
values between 10 and 50 ng/ml, and they were referred
for facilitated follow-up in urology.
Finally, we compared other comorbid conditions be-
tween cases and controls (Table 3). As expected cases
reported a higher prevalence of benign prostatic hyper-
plasia: 62% vs. 8% (p < 0.0001) in comparison to con-
trols. Controls had a higher prevalence of high blood
pressure in comparison to cases (60% vs. 42%; p = 0.07),
whereas the prevalence of other comorbidities was not
significantly different between the two groups. None of
the cases or controls reported a history of infectious
diseases including HIV/AIDS, hepatitis, syphilis or her-
pes infection.
Discussion
Cancer is a major cause of morbidity and mortality
worldwide, and its burden is projected to increase by
70% over the next 20 years [34]. The recent World Re-
port on Cancer indicates that by 2030 the majority of
the population affected by cancer will be in low- and
middle-income countries (LMIC), as they transition to-
wards higher levels of the Human Development Index,
with concomitant increasing life span, aging popula-
tions, and rapid changes of socio-economic and lifestyle
factors [34]. Data from the GLOBOCAN program of
IARC show that in Nigeria, PrCa is the leading cancer
affecting men, which accounts for 18.2% and 17.7% of
all cancer-related diagnoses and deaths, respectively
[34,35]. Like other LMIC, efforts in Nigeria to develop
cancer prevention and control programs have been
hampered by lack of investment in health care infra-
structure with multiple competing health priorities.
Given that Nigeria is the most populous country in
Africa, there is a need to address important gaps in our
current knowledge about the etiology of PrCa in Nigerian
men, particularly in relation to aggressive forms of this
cancer.
The goals of this collaborative study between the
Albert Einstein College of Medicine and the University
College Hospital in Ibadan, Nigeria, were to assess the
feasibility of conducting an epidemiological case–con-
trol study of PrCa at the latter institution, and to obtain
preliminary insight into PrCa risk factors in Nigerian
men. This pilot study demonstrated the ability to ascer-
tain and recruit successfully 50 cases and 50 controls at
UCH with very good participation rates of 98% and 93%,
respectively. In addition, all participants completed an
in-person questionnaire, and 100% of cases and 99% of
controls provided blood sample. Our results highlighted
Table 2 Anthropometric, lifestyle and dietary characteristics among prostate cancer cases and controls
Lifestyle characteristics Cases (n = 50) Controls (n = 50) P OR* 95% CI
Height (cm); mean sd 163.02 9.6 168.87 6.89 0.001 0.91† 0.86 0.97
Weight (kg); mean sd 67.84 12.10 72.35 11.85 0.06 0.97† 0.94 1.00
Waist size (cm); mean SD 80.44 9.33 88.92 10.53 <0.0001 0.91† 0.87 0.96
Body mass index (BMI; kg/m2) mean sd 25.68 0.68 25.33 0.51 0.69 1.02† 0.93 1.12
BMI category; n %
<25 21 42.0 25 50.0 0.72 1.00 -
25 - 29.9 21 42.0 18 36.0 1.39 0.59 3.28
≥30 8 16.0 7 14.0 1.35 0.42 4.36
Weight change ≥5 kg in last year <0.0001
No change 21 42.0 41 82.0 1.00 -
Increased 3 6.0 1 2.0 6.08 0.59 62.59
Decreased 26 52.0 8 16.0 6.78 2.56 7.97
Moderate physical activity; n % 0.24
Never or 1–3 times / month 13 26.0 19 38.0 1.00 -
1- 6 times / week 13 26.0 15 30.0 1.26 0.45 3.57
Every day 24 48.0 16 32.0 2.19 0.85 5.67
Cigarette smoking status, n % 0.32
Never smoker 29 58.0 33 66.0 1.00
Former smoker Quit≤ 27 years‡ 11 22.0 7 14.0 1.79 0.61 5.23
Quit > 27 years‡ 10 20.0 7 14.0 1.67 0.56 5.00
Current smoker - - 2 4.0 -
Pack-years of smoking, n % 0.65
Non-Smoker 29 58.0 33 66.0 1.00 -
1-9.9 12 24.0 9 18.0 1.46 0.54 3.95
≥10 6 12.0 7 14.0 0.94 0.28 3.10
Alcohol consumption, n % <0.0001
Never user 7 14.0 19 38.0 1.00 -
Former user 39 78.0 20 40.0 5.20 1.86 14.56
Current user 3 6.0 10 20.0 0.82 0.16 3.84
Missing 1 2.0 1 2.0
Years since stopped drinking (former users); mean sd 16.57 2.17 26.68 2.91 0.008 0.94† 0.89 0.98
Drinks/week (current and former users); mean sd 1.27 0.92 3.91 5.41 0.014 0.72† 0.49 1.06
Dietary intake n % n % P OR* 95% CI
Red meat, n % 0.72
Never 8 16.0 7 14.0 1.00 -
1- 3 times/month 7 14.0 11 22.0 0.56 0.14 2.30
1- 4 times/week 18 36.0 16 32.0 0.99 0.28 3.43
≥1 times/day 16 32.0 16 32.0 0.88 0.25 3.04
Pork, n % 0.40
Never 48 96.0 46 92.0 1.00 -
1- 3 times/month 2 4.0 4 8.0 0.48 0.08 2.75
Chicken, n % 0.15
Never 16 32.0 7 14.0 1.00 -
1 - 3 times/month 20 40.0 25 50.0 0.35 0.12 1.01
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Table 2 Anthropometric, lifestyle and dietary characteristics among prostate cancer cases and controls (Continued)
1 - 4 times/week 14 28.0 17 34.0 0.36 0.12 1.12
Smoked foods, n % 0.24
Never 8 16.0 7 14.0 1.00 -
1 - 3 times/month 9 18.0 18 36.0 0.44 0.12 1.59
1 - 4 times/week 27 54.0 20 40.0 1.18 0.37 3.80
≥1 times/day 6 12.0 5 10.0 1.05 0.22 5.02
Fish, n % 0.68
1- 3 times/month 5 10.0 4 8.0 1.00 -
1 - 4 times/week 27 54.0 24 48.0 1.14 0.29 4.45
≥1 times/day 18 36.0 21 42.0 0.86 0.21 3.45
Vegetables, n % 0.07
1-3 times/month 4 8.0 4 8.0 1.00 -
1 - 4 times/week 24 48.0 13 26.0 1.89 0.40 8.90
≥1 times/day 22 44.0 33 66.0 0.68 0.15 3.01
Fruits, n % 0.80
Never 4 8.0 3 6.0 1.00 -
1 - 3 times/month 6 12.0 5 10.0 0.89 0.13 6.12
1 - 4 times/week 25 50.0 30 60.0 0.62 0.13 3.05
≥1 times/day 15 30.0 12 24.0 0.93 0.17 5.01
Saturated fats, n % 0.08
Never 42 84.0 33 66.0 1.00 -
1 - 3 times/month 3 6.0 10 20.0 0.23 0.06 0.92
1 - 4 times/week 5 10.0 7 14.0 0.56 0.16 1.92
Oils (olive, canola), n % 0.003
Never 17 34.0 8 16.0 1.00 -
1 - 3 times/month 7 14.0 6 12.0 0.55 0.14 2.18
1 - 4 times/week 18 36.0 11 22.0 0.77 0.25 2.38
≥1 times/day 8 16.0 25 50.0 0.15 0.05 0.48
Fried food, n % 0.26
Never 7 14.0 7 14.0 1.00 -
1 - 3 times/month 7 14.0 13 26.0 0.54 0.13 2.17
1 - 4 times/week 31 62.0 22 44.0 1.41 0.43 4.61
≥1 times/day 5 10.0 8 16.0 0.63 0.14 2.91
Carbohydrates/Pastry, n % 0.69
0 - 3 times/month 1 2.0 2 4.0 1.00 -
1 - 4 times/week 6 12.0 8 16.0 1.51 0.11 0.85
≥1 times/day 43 86.0 40 80.0 2.15 0.19 24.66
Milk / Yogurt, n % 0.07
Never 10 20.0 10 20.0 1.00 -
1 - 3 times/month 7 14.0 13 26.0 0.54 0.15 1.93
1 - 4 times/week 26 52.0 14 28.0 1.86 1.62 5.53
≥1 times/day 7 14.0 13 26.0 0.54 0.15 1.92
Carbonated drinks, n % 0.24
Never 25 50.0 24 48.0 1.00 -
1 - 3 times/month 10 20.0 16 32.0 0.60 0.23 1.58
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Table 2 Anthropometric, lifestyle and dietary characteristics among prostate cancer cases and controls (Continued)
1 - 4 times/week 14 28.0 10 20.0 1.34 0.50 3.60
Coffee/Tea, n % 0.49
Never 21 42.0 15 30.0 1.00 -
1 - 3 times/month 5 10.0 7 14.0 0.51 0.13 1.92
1 - 4 times/week 13 26.0 11 22.0 0.84 0.30 2.39
≥1 times/day 11 22.0 16 32.0 0.49 0.17 1.36
*OR and 95% CI were estimated from logistic regression models adjusted for age; OR = 1.00 refers to the reference category.
†OR and 95% CI for these variables are expressed per one unit increase.
‡The cutoff point for years of quitting smoking was based on the median in controls (27 years).
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and that family history of PrCa and some anthropomet-
ric factors (e.g. height, weight and waist circumference)
were associated with PrCa risk in this population.
Our pilot data demonstrated that the majority of PrCa
patients at UCH were diagnosed at an older age and had
more aggressive clinical features (the median diagnostic
PSA was 72.9 ng/ml, and 38% had a Gleason score of 8–
10 tumor), in comparison to PrCa patients diagnosed in
the US or other developed countries [2]. Information on
clinical stage of PrCa was not available. However, approxi-
mately 90% of our PrCa patients might have had regional
or metastatic tumor at diagnosis because they were
treated with radiation and/or hormone therapy. A limita-
tion is that tumor staging is not performed routinely in
clinical practice in Nigeria. Thus, implementation of clin-
ical staging by urologists and pathologists would better
characterize not only the clinical features of PrCa but also
help improve decision-making regarding PrCa treatment.
Our results are consistent with those of several other case
reports [37,39-43] showing that 65%-80% of all PrCa pa-
tients in Nigeria are diagnosed with advanced tumor grade
and stage. In addition, a recent community-based PrCa
awareness program, which was conducted among 4,110
men aged 40 years or older in Lagos, a major urban center
near Ibadan, reported that 56%, 28% and 35% of 43 men
diagnosed with PrCa through this program had a diagnos-
tic PSA ≥20 ng/ml, Gleason score 8–10, and metastatic
disease, respectively [41].
Collectively these data indicate that either PrCa is more
aggressive among African men or there is a lack of PrCa
screening programs, which would shift the clinical features
of this cancer. Although 98% of our PrCa patients re-
ported having had a serum PSA or digital rectal exam
(DRE) before their cancer diagnosis, these are likely diag-
nostic tests rather than preventive screening tests. Data
from our controls showed that 80% of men had not had
any PSA or DRE tests done, indicating the lack of PrCa
preventive screening programs in Nigeria. The issue of
PrCa screening is the subject of ongoing debate, especially
after the U.S. Preventive Service Taskforce recommended
against PSA screening in 2012 (D grade) [45]. While thisdecision considered many aspects of PSA screening includ-
ing over-diagnosis and overtreatment of PrCa, the recom-
mendation was based on conflicting results from two large
PrCa screening trials conducted in the US [46,47] and
Europe [48,49]. The PLCO trial in the US did not report
any benefit of PSA screening on PrCa-specific mortality
[46,47], while the European trial reported a statistically sig-
nificant 21% reduction in PrCa-specific mortality associ-
ated with PSA screening at 13 years of follow-up [48,49].
However, a limitation of both trials is that they did not ad-
dress the benefit of screening in high-risk populations,
namely men of African descent or those with a family his-
tory of PrCa. While there is an ongoing discussion to im-
plement shared decision making between primary care
physicians and their patients about risks and benefits of
screening in developing countries, such as the U.S. [50],
the current screening guidelines for Nigeria and other
LMIC in Africa are less clear. This suggests that further
studies are needed to assess the benefits of PSA screening
in African men, and those with family history of PrCa. Al-
though our study was not designed to address this issue,
we note that some discussion about PrCa screening in
Nigeria needs to be implemented between patients and
health care practitioners or physicians.
In our pilot study we also collected information on vari-
ous risk factors for PrCa in Nigerian men. Consistent with
other PrCa studies [10,11], a first-degree family history of
PrCa was associated with a 4.9-fold increased risk (95% CI
1.0 - 24.8) of PrCa in our data. However, self-reported
family history for second-degree relatives was limited. The
accuracy of self-reported cancer in relatives depends
largely on family size as well as knowledge about cancer
diagnosis in relatives. Although the average family size is
relatively large in Nigeria, knowledge about PrCa or family
history of this disease might be limited for several reasons
including undiagnosed cancer, low health literacy about
PrCa, as well as social stigma around cancer in Nigerians.
For example, in a cross-sectional study of 156 urban men
in Nigeria, Ajape et al. [51] reported that 79% and 94% of
them, respectively, had never heard any information on
PrCa or PSA screening. Thus it is important to raise
awareness on PrCa among Nigerian men.
Table 3 Clinical characteristics, medical comorbidities and information about prostate cancer screening and serum PSA
levels in cases and controls
Characteristics Cases (n = 50) Controls (n = 50)
n % n %
Age at prostate cancer diagnosis (years)
<50 1 2.0
50 - 59 4 8.0
60 - 69 20 40.0
70 - 79 25 50.0
Reason for prostate cancer diagnosis
Abnormal PSA only 1 2.0
Abnormal PSA or DRE & Symptoms 5 10.0
Symptoms only 38 76.0
Don’t know 6 12.0
Gleason score
4 - 6 12 24.0
7 16 32.0
8 - 10 18 36.0
Missing 4 8.0
Serum PSA (ng/dl)*
<4 1 2.0 36 72.0
4 - 9.9 5 10.0 9 18.0
10 - 19.9 4 8.0 - -
20 - 49.9 4 8.0 4 8.0
50 - 135 31 62.0 - -
Missing* 5 10.0 1 2.0
Prostate cancer screening
No screening (either PSA or DRE) - - 40 80.0
PSA only or DRE only 8 16.0 4 8.0
PSA and DRE (both) 41 82.0 6 12.0
Unknown / missing 1 2.0 - -
Current health
Excellent 1 2.0 3 6.0
Very Good 1 2.0 9 18.0
Good 20 40.0 21 42.0
Fair 25 50.0 15 30.0
Poor 3 6.0 2 4.0
Comorbid conditions;
Asthma 1 2.0 3 6.0
High blood pressure 21 42.0 30 60.0
Stroke 1 2.0 2 4.0
Diabetes 6 12.0 7 14.0
High cholesterol - - 3 6.0
Ulcers 2 4.0 6 12.0
Chronic back pain 3 6.0 5 10.0
Benign prostatic hyperplasia (BPH) 31 62.0 4 8.0
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levels in cases and controls (Continued)
Urinary tract infections/STD 2 4.0 2 4.0
Use of Traditional Medicine (Current) 11 22.0 12 24.0
Nr of physical exams (past 3 yrs); mean; sd 7.0 11.4 6.2 8.5
Nr of traditional healer visits; mean sd 9.4 17.8 1.7 2.7
*For cases serum PSA indicates the diagnostic PSA, which was abstracted from medical records. For controls serum PSA levels were measured from the blood
samples that they provided during in-person interview. One control did not provide a blood sample.
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observed statistically significant inverse associations be-
tween risk of PrCa and height, weight and waist circum-
ference, there was no association with body mass index.
The inverse association with weight may be due to the
fact that the proportion of men who had lost 5 kg or
more in the past year was much higher in cases in com-
parison to controls (52% vs. 16%; p < 0.0001), which could
be attributed to cachexia due to cancer. For lifestyle and
dietary factors we did not find any clear trends or associ-
ations with PrCa risk. However, the sample size of this
study was very small and we had limited power for com-
prehensive data analyses. Larger epidemiological studies
will be needed for more definitive investigation of the as-
sociation between several lifestyle and dietary factors and
risk of PrCa in this population.
Some feasibility issues to be considered for large epide-
miologic studies in hospital settings in Africa include the
number of PrCa patients that are seen on an annual basis,
potential delays in recruitment of patients, and the infra-
structure for processing and long term storage of blood/
serum samples, communication issues, and challenges
with abstracting data from medical charts. The UCH sees
on average 140 PrCa patients per year. Thus for large
studies (e.g. 500 cases/500 controls) a 4 to 5- year recruit-
ment period is needed in order to achieve the required
sample size, assuming ≥80% participation rate. Our study
was delayed due to strikes that affected hospital adminis-
tration, which could potentially affect larger studies.
There were limitations surrounding infrastructure in la-
boratories and bio-specimen storage. In our study we ex-
tracted DNA soon after blood collection and DNA
samples are currently stored at −20°C in different labora-
tories at UCH. However, in order to conduct large-scale
epidemiological studies among thousands of patients,
there is a need to build a central biorepository, which
could be used for long-term storage of DNA, serum or
plasma samples at −80°C for future research, as is done
in most developed countries. We also encountered diffi-
culties in communication via phone or internet between
the research teams in Ibadan and New York. Regular
phone or Skype communication on a bi-weekly or
monthly basis was necessary to coordinate different re-
search activities and maintain collaboration, and thequality of these interactions was impaired when the con-
nection was poor. Finally, secondary extraction of clinical
and laboratory data from medical charts for some pa-
tients was challenging due to missing detailed reports on
medical charts. Thus, establishment of an electronic
medical records system will be very useful in capturing
the minimum clinical/pathological data for PrCa that can
be used for research.
As with other case–control studies, another limitation of
our study includes the potential for selection bias and re-
call bias. The UCH is a major tertiary hospital in Ibadan
and thus patients who are admitted to this hospital might
not be representative of the entire general population i.e.,
the referral filter bias. Since there is no national health in-
surance program in Nigeria and most hospital expenses
are paid out of pocket, there is a possibility that both cases
and controls who are hospitalized at UCH are different
from men in the general population particularly those in
the rural areas, and thus, the generalizability of the results
may be limited. Another potential bias could be misclassifi-
cation of outcome since some of the controls with high
PSA levels may have had underlying PrCa. Five out of nine
controls with serum PSA values between 4 and 10 ng/ml
reported having had either a benign enlargement of their
prostate (BPH) or urinary tract infection. Although all con-
trols with serum PSA >4 ng/ml were referred for additional
follow-up with Urology, we were not able to ascertain what
proportion of these controls had underlying PrCa. In a
large community-based PrCa awareness study in Lagos,
the prevalence of PrCa among 4,110 men aged >40 years
was 1.1% [41]. However, another large population-based
PrCa screening study of 1,037 healthy men aged 50 to
74 years in Ghana [52] reported a higher PrCa prevalence
of 7%. Thus, we anticipate that one to three controls in our
study may potentially have had an underlying PrCa, a con-
sequence of which would have been to bias case–control
differences towards the null. In order to address potential
outcome misclassification we conducted a sensitivity ana-
lysis by excluding controls with a serum PSA >10 ng/ml
(n = 4), who might possibly have had an underlying PrCa.
In these analyses, associations between PrCa risk and ei-
ther family history of PrCa or anthropometric, demo-
graphic and lifestyle characteristics were similar to those
observed using all controls (data not shown). Lastly, as in
Agalliu et al. BMC Public Health  (2015) 15:425 Page 11 of 12studies elsewhere, participants in our study might have
misreported sensitive information, such as infectious dis-
eases, as none of the participants reported HIV/AIDS,
hepatitis, syphilis or herpes infection.
Conclusions
This pilot study of PrCa demonstrated the ability to ascer-
tain and recruit participants as well as to collect data suc-
cessfully at UCH in Ibadan, Nigeria. Our results highlighted
the advanced clinical characteristics of PrCa in Nigerian
men, and that family history of PrCa and some anthropo-
metric factors were associated with PrCa risk in this popu-
lation. This study also represents a small step forward in
addressing the need to build collaborative research partner-
ships in cancer. The ultimate objective of our study is to es-
tablish and sustain a platform for continual development of
research and clinical capacities for PrCa research. As part
of this collaboration we (UCH and Einstein) are now part
of the Men of African Descent and Carcinoma of the Pros-
tate Consortium [9,53], which aims to undertake research
that will improve understanding of the etiology, genetics,
prevention, and treatment of PrCa in Africa.
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